Navigation Links
Researchers study vaccine as potential weapon against aggressive brain tumors
Date:7/24/2012

CHICAGO Researchers at Northwestern Brain Tumor Institute (NBTI) are seeking to understand if a vaccine made from a patient's own blood cells may slow the growth of a type of brain tumor. The trial is studying the vaccine's effect on glioblastoma multiformes (GBM), the most common and aggressive type of primary brain tumor. The trial is an example of a growing trend in cancer research that seeks to understand if vaccines can be used to turn a person's own immune system into a weapon against cancers by slowing the growth of tumors.

GBMs, which occur in up to 10,000 Americans annually, are typically treated with surgical resection of the tumor followed by chemotherapy and radiation treatment. "Glioblastomas are complicated to treat because they are aggressive, fast-growing tumors that are often resistant to standard treatment," said principal investigator James Chandler, MD, co-director of the NBTI and surgical director of neuro-oncology at Northwestern Memorial Hospital. "In this trial, a vaccine is made using the person's own white blood cells, which we hope will have the power to stimulate an immune response to kill brain tumor cells."

The vaccine, called ICT-107, is created by collecting the participant's white blood cells through a process called apheresis, which separates the components in the blood. The white blood cells are then treated to recognize the tumor cells turning them into immune cells, which early research indicates may be able to recognize and attack the tumor cells. Patients receive the vaccine in addition to standard treatment.

"Vaccines hold great promise as potential treatments for all types of cancer," said Chandler, who is also a professor of neurological surgery at Northwestern University Feinberg School of Medicine. "More researchers are looking at this as a way to prompt an immune response to slow tumor growth and fight the cancer."

The phase II trial will examine both safety and efficacy of the ICT-107 vaccine. Researchers seek to enroll approximately 225 participants nationally who are newly diagnosed with a GBM. To be considered for enrollment, a person must be 18 years or older and not have a recurrent disease or any other active malignancy or history of malignancy. They must have undergone surgery to excise the GBM, but have not yet started chemotherapy or radiation. Full inclusion and exclusion criteria can be found on ClinicalTrials.gov.

"GBMs are a devastating diagnosis and these patients unfortunately are not given a great deal of time," said Chandler. "Our goal at Northwestern Brain Tumor Institute is to provide patients with the best options to treat their cancer in a manner that not only gives them longer lives, but also improved quality of life."


'/>"/>

Contact: Megan McCann
memccann@nmh.org
312-926-5900
Northwestern Memorial Hospital
Source:Eurekalert

Related medicine news :

1. Researchers developing bioadhesive gel to protect women from HIV and HSV infections
2. Researchers find driver of breast cancer stem cell metastasis
3. Researchers unfold the mechanisms underlying blood disorders
4. New lipid screening guidelines for children overly aggressive, UCSF researchers say
5. BUSM researchers identify genetic markers for testosterone, estrogen level regulation
6. UGA researchers develop rapid diagnostic test for pathogens, contaminants
7. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
8. Researchers link Kawasaki Disease in childhood with increased risk of adult heart disease
9. Researchers to use novel metabolomics technology for COPD
10. Researchers hit back at early bodycheck theory
11. Cleveland Clinic researchers discover molecule that may prevent atherosclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... Five Star Glass is new to the Texas market, but ... of auto glass for most makes and models, in Grand Prairie, TX, located in the ... They have been a family owned business for the past 40 years with 32 convenient ...
(Date:8/22/2017)... ... , ... “Glimpses Of Light”: is a unique and thought inspiring guide ... creation of published author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author ... , Shepherd shares, “Love is one of the least understood and yet most sought-after ...
(Date:8/21/2017)... MO (PRWEB) , ... August 22, 2017 , ... PracticeMatch, ... fairs to help healthcare employers connect with physicians and advanced practitioners like nurse ... virtual career fairs in August through November of this year. The online career ...
(Date:8/21/2017)... ... 2017 , ... SportsEngine, Inc. , a division of ... of North Country Region Volleyball and will power registration, scheduling, and competition results ... sport management software to their member clubs. , SportsEngine provides financial ...
(Date:8/21/2017)... ... , ... PIXACORE , an independent full-service agency with a decade of ... the year by MM&M. , This is the first time PIXACORE has made the ... agency. PIXACORE’s newfound recognition reflects its steady trajectory of growth and recent strategic ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... 2017 Three Tru-D SmartUVC robots have arrived at ... . Tru-D, short for "Total Room Ultraviolet Disinfection," is a 5-foot-5 ... environmental services (ES) professional cleans the area with traditional cleaning protocols. ... Tru-D fights germs at ... "Although the BAACH has a very low ...
(Date:7/27/2017)... 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... June 30, 2017.  The Company reported second quarter net ... the prior year period, and an increase of 2.1% ... points of contribution from the LDR Holding Corporation acquisition, ... quarter of 2016, or 0.3% on a constant currency ...
(Date:7/26/2017)... 26, 2017 Sancilio Pharmaceuticals Company, Inc. (SPCI) ... trial evaluating Altemia TM , an oral therapy for ... Cell Disease (SCD). The SCOT Trial, is a double-blind, ... safety of Altemia TM in pediatric patients aged ... IND 125274. "The ...
Breaking Medicine Technology: